United Therapeutics Commences Litigation to Ensure Fairness in the Drug Review Process
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR) announced today the commencement... Read more.
Axians Switzerland Partners With Sectigo To Bring Cloud-Native Certificate Lifecycle Management to Their Customers
Organizations join forces to deliver CLM for all SCOTTSDALE, Ariz.–(BUSINESS WIRE)–Sectigo®, the industry’s most innovative provider of comprehensive... Read more.
Vertiv Reports Strong Fourth Quarter Results and Provides Full Year 2024 Outlook
Fourth quarter net sales of $1,865 million, 13% higher than the fourth quarter of 2022 Fourth quarter organic orders up 23% from fourth quarter 2022. Record high... Read more.
T-Mobile Czech selects Mavenir for Cloud Native Converged Packet Core Solution
BARCELONA, Spain–(BUSINESS WIRE)–#5G–Mavenir, the cloud-native network infrastructure provider building the future of networks, today announces... Read more.
Eutelsat Group’s ADVANCE Maritime Offer Supporting Universal Satcom to Consolidate and Extend Its Service Offering
PARIS–(BUSINESS WIRE)–Regulatory News: Eutelsat Group (ISIN: FR0010221234 – Euronext Paris / London Stock Exchange: ETL) (Paris:ETL) (LSE:ETL),... Read more.
Aqua Comms Appoints Andy Hudson as Acting CEO
DUBLIN–(BUSINESS WIRE)–#CEO—Aqua Comms (“Aqua Comms”), a leading provider of global subsea connectivity services, has announced today that... Read more.
At Least Four-in-Ten Campaigns Will Run on CTV in the Next Two Years, According to OpenX and ExchangeWire Research
A new study reveals trends in CTV, targeting, and sustainability for the European digital media industry. PASADENA, Calif.–(BUSINESS WIRE)–As the programmatic... Read more.
Powin and Pulse Clean Energy Partner on a 50 MW / 110 MWh UK Battery Energy Storage System
This project will increase grid reliability and resiliency, and enable greater renewables integration while helping the UK hit net zero targets PORTLAND, Ore. &... Read more.
Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development Announce First Patient Dosed in ALETA-001 Phase 1/2 Clinical Trial in Patients with Relapsed/Refractory B-Cell Malignancies
The Phase 1/2 clinical trial will evaluate safety, dose, PK/PD, and early efficacy signals of Aleta’s first-in-class biologic CAR T-Cell Engager, ALETA-001 ALETA-001... Read more.
United Partners and the European Union Unveil “Cohesion Story Quest” – A Groundbreaking Communication Endeavor
SOFIA, Bulgaria–(BUSINESS WIRE)–#EUStoryQuest–In a bold move blending digital innovation with grassroots storytelling, United Partners, a premier... Read more.